Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,906 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Hirsch L, et al. Among authors: xu w. JAMA Oncol. 2021 Dec 1;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544. JAMA Oncol. 2021. PMID: 34673916 Free PMC article.
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.
Saliby RM, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane MH, Madsen KN, Ficial M, Hirsch L, Wei XX, Steinharter JA, Harshman LC, Vaishampayan UN, Severgnini M, McDermott DF, Lee GM, Xu W, Van Allen EM, McGregor BA, Signoretti S, Choueiri TK, McKay RR, Braun DA. Saliby RM, et al. Among authors: xu w. Cancer Immunol Res. 2023 Aug 3;11(8):1114-1124. doi: 10.1158/2326-6066.CIR-22-0996. Cancer Immunol Res. 2023. PMID: 37279009 Free PMC article.
Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes.
Xu W, Gaborieau V, Niman SM, Mukeria A, Liu X, Maremanda KP, Takakura A, Zaridze D, Freedman ML, Xie W, McDermott DF, Choueiri TK, Catalano PJ, Sabbisetti V, Bonventre JV, Pierorazio PM, Singla N, Brennan P, Bhatt RS. Xu W, et al. J Clin Oncol. 2024 Aug 1;42(22):2691-2701. doi: 10.1200/JCO.23.00699. Epub 2024 May 3. J Clin Oncol. 2024. PMID: 38701382
Checkpoint inhibitor immunotherapy in kidney cancer.
Xu W, Atkins MB, McDermott DF. Xu W, et al. Nat Rev Urol. 2020 Mar;17(3):137-150. doi: 10.1038/s41585-020-0282-3. Epub 2020 Feb 4. Nat Rev Urol. 2020. PMID: 32020040 Review.
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Braun DA, et al. Among authors: xu w. Cancer Cell. 2021 May 10;39(5):632-648.e8. doi: 10.1016/j.ccell.2021.02.013. Epub 2021 Mar 11. Cancer Cell. 2021. PMID: 33711273 Free PMC article.
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis.
Riaz IB, Sipra QUAR, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Riaz IB, et al. Among authors: xu w. Crit Rev Oncol Hematol. 2022 Jul;175:103706. doi: 10.1016/j.critrevonc.2022.103706. Epub 2022 May 7. Crit Rev Oncol Hematol. 2022. PMID: 35537621 Review.
29,906 results
You have reached the last available page of results. Please see the User Guide for more information.